MONOPAR THERAPEUTICS (MNPR) Social Stream



MONOPAR THERAPEUTICS (MNPR): $1.97

-0.05 (-2.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MNPR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 491

in industry

Monopar Therapeutics (MNPR) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering MNPR.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-15 4 $49 $9 $32.666 $2.61 1151.57%
2022-02-16 3 $49 $9 $27.25 $2.61 944.06%
2022-03-25 4 $49 $9 $27.25 $2.61 944.06%

The Trend in the Analyst Price Target


MNPR's average price target has moved down $7.75 over the prior 14 months.

Over the past 50 weeks, MNPR's average upside potential has been 587.18%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-04-10 0 49 11 35.00 5.61 523.89%
2021-05-15 0 49 11 35.00 5.11 584.93%
2021-06-26 0 49 11 35.00 6.36 450.31%
2021-08-28 0 49 11 33.25 4.97 569.01%
2021-09-19 0 49 11 33.25 5.27 530.93%

MNPR Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 4 0 0 0 0 4

The Trend in the Broker Recommendations


MNPR's average broker recommendation rating improved by 1 over the prior 151 days.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • In terms of how Monopar Therapeutics fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is greater than 296.92% of that group.
  • In terms of how Monopar Therapeutics fares relative to all US stocks, note that its variance in analysts' estimates is lower than -191.01% of that group.
  • In terms of how Monopar Therapeutics fares relative to stocks in the micro market cap category, note that its average analyst price target is greater than 273.21% of that group.
  • In terms of how Monopar Therapeutics fares relative to Pharmaceutical Products stocks, note that its number of analysts covering the stock is greater than 58.56% of that group.

In the Pharmaceutical Products industry, MDNA, MBRX, and LTRN are the three stocks most similar to Monopar Therapeutics regarding the price target and analyst recommendation information presented here.

Is MNPR a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.8574 seconds.